Pralsetinib (BLU-667) is a second, potent, ATP-competitive, selective RET TKI which has been approved by the FDA for the treatment of RET fusion-positive NSCLC and RET-altered thyroid cancers based on the results of the registrational ARROW trial [152,153]. Here, RET is linked to non-small cell lung carcinoma.